See more : C3.ai, Inc. (AI) Income Statement Analysis – Financial Results
Complete financial analysis of IMAC Holdings, Inc. (BACK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IMAC Holdings, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Kaji Technology Corporation (6391.T) Income Statement Analysis – Financial Results
- Sierra Grande Minerals Inc. (SGRO.CN) Income Statement Analysis – Financial Results
- Iris Clothings Limited (IRISDOREME.NS) Income Statement Analysis – Financial Results
- The Chugoku Bank, Limited (8382.T) Income Statement Analysis – Financial Results
- Sical Logistics Limited (SICALLOG.BO) Income Statement Analysis – Financial Results
IMAC Holdings, Inc. (BACK)
About IMAC Holdings, Inc.
IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20M | 16.19M | 14.39M | 12.84M | 15.13M | 6.70M | 786.03K | 15.00K |
| Cost of Revenue | 1.35M | 1.51M | 1.63M | 1.62M | 2.54M | 933.91K | 63.22K | 4.27K |
| Gross Profit | 3.85M | 14.68M | 12.76M | 11.21M | 12.59M | 5.77M | 722.81K | 10.73K |
| Gross Profit Ratio | 74.05% | 90.68% | 88.68% | 87.35% | 83.21% | 86.06% | 91.96% | 71.56% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | -6.26K | 21.80M | 19.73M | 15.44M | 15.98M | 7.81M | 1.45M | 204.78K |
| Selling & Marketing | 7.73K | 1.10M | 1.32M | 933.34K | 1.24M | 859.19K | 119.87K | 25.00K |
| SG&A | 1.47K | 22.90M | 21.06M | 16.38M | 17.22M | 8.67M | 1.57M | 229.78K |
| Other Expenses | 0.00 | 1.63M | 1.65M | 1.31M | 1.55M | 18.36K | 65.90K | 0.00 |
| Operating Expenses | 5.03M | 24.53M | 22.71M | 17.68M | 18.77M | 9.32M | 1.64M | 229.78K |
| Cost & Expenses | 6.38M | 26.03M | 24.33M | 19.31M | 21.31M | 10.25M | 1.70M | 234.05K |
| Interest Income | 0.00 | 10.58K | 2.89K | 6.07K | 7.79K | 7.54K | 14.82K | 4.00 |
| Interest Expense | 0.00 | 14.19K | 504.10K | 563.07K | 897.69K | 153.82K | 27.15K | 4.00 |
| Depreciation & Amortization | 403.59K | 1.63M | 1.65M | 1.72M | 1.55M | 651.07K | 65.90K | 219.05K |
| EBITDA | -5.95M | -10.20M | -8.39M | -3.26M | -4.50M | -2.98M | -823.48K | -397.44K |
| EBITDA Ratio | -114.43% | -50.91% | -57.28% | -36.96% | -30.68% | -44.47% | -104.42% | -2,649.60% |
| Operating Income | -6.38M | -9.85M | -9.95M | -6.47M | -6.19M | -3.55M | -915.07K | -219.05K |
| Operating Income Ratio | -122.68% | -60.85% | -69.16% | -50.43% | -40.89% | -53.00% | -116.42% | -1,460.31% |
| Total Other Income/Expenses | -99.85K | 6.11K | -443.89K | 993.86K | -765.96K | -233.48K | -1.47K | -178.39K |
| Income Before Tax | -6.48M | -18.31M | -10.54M | -5.54M | -6.95M | -3.78M | -916.53K | -397.44K |
| Income Before Tax Ratio | -124.60% | -113.14% | -73.28% | -43.18% | -45.96% | -56.48% | -116.60% | -2,649.60% |
| Income Tax Expense | 0.00 | 8.43M | 561.43K | 24.37K | 427.20K | -79.65K | -818.59K | -16.65K |
| Net Income | -9.42M | -26.74M | -11.10M | -5.57M | -7.38M | -3.05M | -57.18K | -380.80K |
| Net Income Ratio | -181.23% | -165.24% | -77.18% | -43.37% | -48.78% | -45.57% | -7.27% | -2,538.65% |
| EPS | -7.36 | -28.38 | -14.77 | -15.11 | -28.55 | -12.65 | -0.38 | -2.56 |
| EPS Diluted | -7.36 | -28.38 | -14.77 | -15.11 | -28.55 | -12.65 | -0.38 | -2.56 |
| Weighted Avg Shares Out | 1.11M | 942.46K | 751.72K | 368.34K | 258.45K | 241.43K | 150.40K | 149.02K |
| Weighted Avg Shares Out (Dil) | 1.11M | 942.46K | 751.72K | 368.34K | 258.45K | 241.43K | 150.40K | 149.02K |
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
FRANKLIN, TN, Nov. 22, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on...
IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)
FRANKLIN, TN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it has received an exception from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance...
IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of an entirely new precision oncology assay for breast cancer treatment decision...
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
FRANKLIN, TN, Aug. 23, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on...
IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors
Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ: BACK) (the “Company” or “IMAC”), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of...
IMAC Holdings Announces Leadership Succession
Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”) today announced leadership transitions to the board of directors and executive team.
IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business
FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ: BACK) (“BACK”) and Theralink Technologies, Inc. (“Theralink”), BACK acquired the...
IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
Franklin, TN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”) today announced that it has received notice from The Nasdaq Stock Market LLC informing the Company that it has regained compliance with the...
IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split
Franklin, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”) today announced a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the “Reverse Split”) and that...
If You Can Only Buy One Penny Stock, It Better Be One of These 3 Names
Penny stocks are generally defined as securities that trade for less than $5 a share. These stocks can be volatile and unpredictable, leading many investors to avoid them.
Source: https://incomestatements.info
Category: Stock Reports